Jennifer Brown, MD, PhD

Jennifer Brown, MD, PhD, from the Dana-Farber Cancer Institute, highlights findings from chronic lymphocytic leukemia (CLL) studies presented at the 2021 American Society of Hematology (ASH) Annual Meeting.  

Dr Brown begins with several studies in the front-line setting. The CLL13 trial compared three venetoclax CD20 antibody regimens in young, fit patients. Most notably, obinutuzumab plus venetoclax demonstrated superiority over chemoimmunotherapy. 

Next, Dr Brown shares results from the FLAIR trial, in which oral ibrutinib plus intravenous rituximab showed superior progression-free survival over oral fludarabine, oral cyclophosphamide, and intravenous rituximab (FCR). 

She also discusses long-term results from a study of ibrutinib plus FCR in younger patients. The rate of undetectable minimal residual disease was sustained and the rate of complete remission increased compared with the initial analysis. 

Dr Brown also reports that in the SEQUOIA trial, zanubrutinib demonstrated superiority in progression-free survival, even in high-risk subgroups. 

In the relapsed/refractory setting, Dr Brown looks at the BRUIN study, in which pirtobrutinib demonstrated promising efficacy in patients who were previously treated with Bruton tyrosine kinase (BTK) inhibitors, as well as promising early data on the novel covalent inhibitor MK-1026.  

Dr Brown concludes with a review of two studies of humoral and T-cell responses to COVID-19 vaccines in patients with CLL, which both underscored the importance of vaccinations, boosters, and follow-up doses in this group. 

--

Jennifer Brown, MD, PhD, Worthington and Margaret Collette Professor of Medicine, Harvard Medical School; Institute Physician, Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham & Women's Hospital, Boston, Massachusetts  

Jennifer Brown, MD, PhD, has disclosed the following relevant financial relationships:  

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Acerta/AstraZeneca; BeiGene; Catapult; Genentech/Roche; Hutchmed; Janssen; MEI Pharma 

Received research grant from: Gilead; Loxo/Lilly; TG Therapeutics; Verastem/SecuraBio 

Jennifer Brown, MD, PhD, from the Dana-Farber Cancer Institute, highlights findings from chronic lymphocytic leukemia (CLL) studies presented at the 2021 American Society of Hematology (ASH) Annual Meeting.  

Dr Brown begins with several studies in the front-line setting. The CLL13 trial compared three venetoclax CD20 antibody regimens in young, fit patients. Most notably, obinutuzumab plus venetoclax demonstrated superiority over chemoimmunotherapy. 

Next, Dr Brown shares results from the FLAIR trial, in which oral ibrutinib plus intravenous rituximab showed superior progression-free survival over oral fludarabine, oral cyclophosphamide, and intravenous rituximab (FCR). 

She also discusses long-term results from a study of ibrutinib plus FCR in younger patients. The rate of undetectable minimal residual disease was sustained and the rate of complete remission increased compared with the initial analysis. 

Dr Brown also reports that in the SEQUOIA trial, zanubrutinib demonstrated superiority in progression-free survival, even in high-risk subgroups. 

In the relapsed/refractory setting, Dr Brown looks at the BRUIN study, in which pirtobrutinib demonstrated promising efficacy in patients who were previously treated with Bruton tyrosine kinase (BTK) inhibitors, as well as promising early data on the novel covalent inhibitor MK-1026.  

Dr Brown concludes with a review of two studies of humoral and T-cell responses to COVID-19 vaccines in patients with CLL, which both underscored the importance of vaccinations, boosters, and follow-up doses in this group. 

--

Jennifer Brown, MD, PhD, Worthington and Margaret Collette Professor of Medicine, Harvard Medical School; Institute Physician, Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham & Women's Hospital, Boston, Massachusetts  

Jennifer Brown, MD, PhD, has disclosed the following relevant financial relationships:  

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Acerta/AstraZeneca; BeiGene; Catapult; Genentech/Roche; Hutchmed; Janssen; MEI Pharma 

Received research grant from: Gilead; Loxo/Lilly; TG Therapeutics; Verastem/SecuraBio 

Jennifer Brown, MD, PhD, from the Dana-Farber Cancer Institute, highlights findings from chronic lymphocytic leukemia (CLL) studies presented at the 2021 American Society of Hematology (ASH) Annual Meeting.  

Dr Brown begins with several studies in the front-line setting. The CLL13 trial compared three venetoclax CD20 antibody regimens in young, fit patients. Most notably, obinutuzumab plus venetoclax demonstrated superiority over chemoimmunotherapy. 

Next, Dr Brown shares results from the FLAIR trial, in which oral ibrutinib plus intravenous rituximab showed superior progression-free survival over oral fludarabine, oral cyclophosphamide, and intravenous rituximab (FCR). 

She also discusses long-term results from a study of ibrutinib plus FCR in younger patients. The rate of undetectable minimal residual disease was sustained and the rate of complete remission increased compared with the initial analysis. 

Dr Brown also reports that in the SEQUOIA trial, zanubrutinib demonstrated superiority in progression-free survival, even in high-risk subgroups. 

In the relapsed/refractory setting, Dr Brown looks at the BRUIN study, in which pirtobrutinib demonstrated promising efficacy in patients who were previously treated with Bruton tyrosine kinase (BTK) inhibitors, as well as promising early data on the novel covalent inhibitor MK-1026.  

Dr Brown concludes with a review of two studies of humoral and T-cell responses to COVID-19 vaccines in patients with CLL, which both underscored the importance of vaccinations, boosters, and follow-up doses in this group. 

--

Jennifer Brown, MD, PhD, Worthington and Margaret Collette Professor of Medicine, Harvard Medical School; Institute Physician, Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham & Women's Hospital, Boston, Massachusetts  

Jennifer Brown, MD, PhD, has disclosed the following relevant financial relationships:  

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Acerta/AstraZeneca; BeiGene; Catapult; Genentech/Roche; Hutchmed; Janssen; MEI Pharma 

Received research grant from: Gilead; Loxo/Lilly; TG Therapeutics; Verastem/SecuraBio